Midazolam nasal spray to treat intermittent, stereotypic episodes of frequent seizure activity: pharmacology and clinical role, a comprehensive review

Cornett, Elyse M.; Nemomsa, Meskerem A.; Turbeville, Bailey C.; Busby, Matthew; Kaye, Jessica S.; Kaye, Aaron J.; Choi, Joo-Hee; Ramírez, Giovanni F.; Varrassi, Giustino; Kaye, Adam M.; Kaye, Alan D.; Wilson, James L; Ganti, Latha

doi:10.52965/001c.38536

Cited by 4 publications

(2 citation statements)

References 37 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Not only does this affect a patient’s quality of life, but it also reduces therapeutic adherence. Nasal spray formulations of commonly used AEDs, such as diazepam and midazolam, have recently been FDA-approved for clinical use [ 137 , 138 ]. Data collected during various clinical trials suggests that both intranasal formulations have improved patient quality of life, are safe for use by children and adolescents, and they are effective at the cessation of seizure clusters and of acute seizures compared to alternative administration routes [ 139 , 140 , 141 , 142 ].…”

Section: Intranasal Drug Deliverymentioning

confidence: 99%

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

et al. 2023

View full text Add to dashboard Cite

Nanomedicine is currently focused on the design and development of nanocarriers that enhance drug delivery to the brain to address unmet clinical needs for treating neuropsychiatric disorders and neurological diseases. Polymer and lipid-based drug carriers are advantageous for delivery to the central nervous system (CNS) due to their safety profiles, drug-loading capacity, and controlled-release properties. Polymer and lipid-based nanoparticles (NPs) are reported to penetrate the blood–brain barrier (BBB) and have been extensively assessed in in vitro and animal models of glioblastoma, epilepsy, and neurodegenerative disease. Since approval by the Food and Drug Administration (FDA) of intranasal esketamine for treatment of major depressive disorder, intranasal administration has emerged as an attractive route to bypass the BBB for drug delivery to the CNS. NPs can be specifically designed for intranasal administration by tailoring their size and coating with mucoadhesive agents or other moieties that promote transport across the nasal mucosa. In this review, unique characteristics of polymeric and lipid-based nanocarriers desirable for drug delivery to the brain are explored in addition to their potential for drug repurposing for the treatment of CNS disorders. Progress in intranasal drug delivery using polymeric and lipid-based nanostructures for the development of treatments of various neurological diseases are also described.

show abstract

Section: Intranasal Drug Deliverymentioning

confidence: 99%

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Needle-free delivery options are particularly beneficial for children, who are more likely to be “needle-phobic”. A range of medications, including midazolam, diazepam, fentanyl, naloxone, ketamine, and dexmedetomidine, among others, are routinely administered intranasally for a variety of indications [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Development of neffy, an Epinephrine Nasal Spray, for Severe Allergic Reactions

Ellis,

Casale,

Kaliner

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Epinephrine autoinjectors (EAIs) are used for the treatment of severe allergic reactions in a community setting; however, their utility is limited by low prescription fulfillment rates, failure to carry, and failure to use due to fear of needles. Given that delayed administration of epinephrine is associated with increased morbidity/mortality, there has been a growing interest in developing needle-free, easy-to-use delivery devices. neffy (epinephrine nasal spray) consists of three Food and Drug Administration (FDA)-approved components: epinephrine, Intravail A3 (absorption enhancer), and a Unit Dose Spray (UDS). neffy’s development pathway was established in conjunction with the FDA and the European Medicines Agency and included multiple clinical trials to evaluate pharmacokinetic and pharmacodynamic responses under a variety of conditions, such as self-administration and allergic and infectious rhinitis, as well as an animal anaphylaxis model of severe hypotension, where neffy demonstrated a pharmacokinetic profile that is within the range of approved injection products and a pharmacodynamic response that is as good or better than injections. The increased pulse rate (PR) and blood pressure (BP) observed even one minute following the administration of neffy confirm the activation of α and β adrenergic receptors, which are the key components of epinephrine’s mechanism of action. The results suggest that neffy will provide a safe and effective needle-free option for the treatment of severe allergic reactions, including anaphylaxis.

show abstract

Nose-to-brain drug delivery for the treatment of CNS disease: New development and strategies

Chen

Liu

et al. 2023

International Review of Neurobiology

View full text Add to dashboard Cite

Midazolam nasal spray to treat intermittent, stereotypic episodes of frequent seizure activity: pharmacology and clinical role, a comprehensive review

Cited by 4 publications

References 37 publications

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

Development of neffy, an Epinephrine Nasal Spray, for Severe Allergic Reactions

Nose-to-brain drug delivery for the treatment of CNS disease: New development and strategies

Contact Info

Product

Resources

About